Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
Standard
Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab. / Augustin, Mathias; Gallo, Gaia; See, Kyoungah; McKean-Matthews, Missy; Burge, Russel; Gooderham, Melinda; Reich, Kristian.
In: J DRUGS DERMATOL, Vol. 21, No. 2, 01.02.2022, p. 122-126.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Early Response is Associated With Stable Long-Term Response in Psoriasis Patients Receiving Ixekizumab or Ustekinumab
AU - Augustin, Mathias
AU - Gallo, Gaia
AU - See, Kyoungah
AU - McKean-Matthews, Missy
AU - Burge, Russel
AU - Gooderham, Melinda
AU - Reich, Kristian
PY - 2022/2/1
Y1 - 2022/2/1
N2 - BACKGROUND: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.OBJECTIVE: To determine early treatment response rates to ixekizumab and ustekinumab and assess whether early response was associated with stable long-term response to these treatments in patients with moderate-to-severe psoriasis.METHODS: This post hoc subgroup analysis of the IXORA-S study (NCT02561806) measured disease severity using the Psoriasis Area Severity Index (PASI) and determined the percentage of patients treated with ixekizumab or ustekinumab who showed PASI 50 at week 2 or 4 (early response) and assessed whether early response was associated with maintaining complete (PASI 100) or almost complete (PASI 90) skin clearance at 80% of monthly visits during weeks 16−52 of treatment (stable response). Nonresponder imputation was used for missing PASI response status.RESULTS: A numerically higher portion of patients treated with ixekizumab were early responders and were significantly more likely to achieve a stable PASI 90 response (P<.0001) or PASI 100 response (P<.0001) than patients treated with ustekinumab. Patients treated with ixekizumab or ustekinumab who were early responders were more likely to achieve a stable response of PASI 90 or 100 (odds ratio>1).CONCLUSION: In patients with moderate-to-severe psoriasis treated with ixekizumab or ustekinumab, early response was a significant factor in maintaining stable complete or almost complete skin clearance. Therefore, rapid response is a clinically relevant factor to consider when optimizing individual therapeutic strategies. J Drugs Dermatol. 2022;21(2):122-126. doi:10.36849/JDD.6063.
AB - BACKGROUND: The identification of early treatment factors that predict the long-term success of maintenance therapy for psoriasis may help optimize individual therapy.OBJECTIVE: To determine early treatment response rates to ixekizumab and ustekinumab and assess whether early response was associated with stable long-term response to these treatments in patients with moderate-to-severe psoriasis.METHODS: This post hoc subgroup analysis of the IXORA-S study (NCT02561806) measured disease severity using the Psoriasis Area Severity Index (PASI) and determined the percentage of patients treated with ixekizumab or ustekinumab who showed PASI 50 at week 2 or 4 (early response) and assessed whether early response was associated with maintaining complete (PASI 100) or almost complete (PASI 90) skin clearance at 80% of monthly visits during weeks 16−52 of treatment (stable response). Nonresponder imputation was used for missing PASI response status.RESULTS: A numerically higher portion of patients treated with ixekizumab were early responders and were significantly more likely to achieve a stable PASI 90 response (P<.0001) or PASI 100 response (P<.0001) than patients treated with ustekinumab. Patients treated with ixekizumab or ustekinumab who were early responders were more likely to achieve a stable response of PASI 90 or 100 (odds ratio>1).CONCLUSION: In patients with moderate-to-severe psoriasis treated with ixekizumab or ustekinumab, early response was a significant factor in maintaining stable complete or almost complete skin clearance. Therefore, rapid response is a clinically relevant factor to consider when optimizing individual therapeutic strategies. J Drugs Dermatol. 2022;21(2):122-126. doi:10.36849/JDD.6063.
KW - Antibodies, Monoclonal, Humanized
KW - Humans
KW - Psoriasis/diagnosis
KW - Severity of Illness Index
KW - Treatment Outcome
KW - Ustekinumab/therapeutic use
U2 - 10.36849/jdd.6063
DO - 10.36849/jdd.6063
M3 - SCORING: Journal article
C2 - 35133112
VL - 21
SP - 122
EP - 126
JO - J DRUGS DERMATOL
JF - J DRUGS DERMATOL
SN - 1545-9616
IS - 2
ER -
